- Home
- BHC vs BLTE Comparison
BHC vs BLTE Comparison
Compare BHC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHC
- BLTE
- Stock Information
- Founded
- BHC N/A
- BLTE 2018
- Country
- BHC Canada
- BLTE United States
- Employees
- BHC N/A
- BLTE N/A
- Industry
- BHC Biotechnology: Pharmaceutical Preparations
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- BHC Health Care
- BLTE Health Care
- Exchange
- BHC Nasdaq
- BLTE Nasdaq
- Market Cap
- BHC 2.3B
- BLTE 2.1B
- IPO Year
- BHC N/A
- BLTE 2022
- Fundamental
- Price
- BHC $6.67
- BLTE $57.70
- Analyst Decision
- BHC Hold
- BLTE Strong Buy
- Analyst Count
- BHC 5
- BLTE 4
- Target Price
- BHC $7.20
- BLTE $96.67
- AVG Volume (30 Days)
- BHC 2.9M
- BLTE 36.3K
- Earning Date
- BHC 07-31-2025
- BLTE 08-08-2025
- Dividend Yield
- BHC N/A
- BLTE N/A
- EPS Growth
- BHC N/A
- BLTE N/A
- EPS
- BHC N/A
- BLTE N/A
- Revenue
- BHC $9,731,000,000.00
- BLTE N/A
- Revenue This Year
- BHC $3.71
- BLTE N/A
- Revenue Next Year
- BHC $5.03
- BLTE N/A
- P/E Ratio
- BHC N/A
- BLTE N/A
- Revenue Growth
- BHC 8.53
- BLTE N/A
- 52 Week Low
- BHC $3.96
- BLTE $43.70
- 52 Week High
- BHC $9.85
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- BHC 76.58
- BLTE 40.14
- Support Level
- BHC $5.93
- BLTE $59.00
- Resistance Level
- BHC $6.55
- BLTE $61.90
- Average True Range (ATR)
- BHC 0.29
- BLTE 1.92
- MACD
- BHC 0.11
- BLTE -0.28
- Stochastic Oscillator
- BHC 98.60
- BLTE 4.67
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.